companiesCompany
Fusion Pharmaceuticals (AstraZeneca)
Alpha-emitter company acquired by AstraZeneca ($2.4B, 2024); FPI-2265 (225Ac-PSMA-I&T) in phase 3.
FPI-2265, FPI-2068 (EGFR×c-MET bispecific radioconjugate), Ac-225 supply agreements.
Pages like this
not linked directly; found by shared links- PairingBeta radioligand → alpha radioligand
Shares Actinium-225 PSMA agents, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- PersonClemens Kratochwil
- CompanyRayzeBio (BMS)
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
- CompanyTerraPower Isotopes
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- CompanyITM Isotope Technologies Munich
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- CompanyBayer
Shares AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617), Actinium-225 PSMA agents.